GlassScriptPhysician profile
Mark Albert Thompson
NPI 1750588661
$11,347.96
in general payments reported to CMS, 2019-2025
26 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $374 · 2021: $927 · 2022: $4,569 · 2023: $2,098 · 2024: $1,935 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,000 · Food and Beverage: $1,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,000.00 |
| Food and Beverage | $1,289.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8,348.70 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $568.70 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $505.29 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $245.95 | 2021-2022 | |
| Boston Scientific Corporation | $168.33 | 2019-2025 | Eluvia, Watchman Access System |
| Lexicon Pharmaceuticals, INC. | $161.51 | 2023-2024 | Inpefa |
| Biotronik INC. | $157.03 | 2019 | |
| Ge Healthcare | $149.97 | 2019 | |
| Tei Biosciences INC | $140.18 | 2019 | |
| Novo Nordisk INC | $139.00 | 2020-2022 | |
| Pacira Pharmaceuticals Incorporated | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $120.59 | 2023 | Verquvo |
| Gilead Sciences, INC. | $115.85 | 2019 | |
| Edwards Lifesciences Corporation | $111.19 | 2020-2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.27 | 2023-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.76 | 2022 | |
| Lantheus Medical Imaging, INC. | $27.12 | 2022 | |
| Amgen INC. | $22.18 | 2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $18.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.54 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.30 | 2021 | |
| Bard Peripheral Vascular, INC. | $17.05 | 2025 | Wavelinq |
| Tactile Systems Technology INC | $14.35 | 2019 | |
| Medtronic Vascular, INC. | $14.33 | 2019 | |
| Bsn Medical INC | $11.71 | 2019 | |
| Elutia, INC. | $6.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.